Medicare Advantage (MA) plans are entering a new era of quality reporting. The transition from traditional hybrid HEDIS® measures to Electronic Clinical Data Systems (ECDS) reporting is accelerating—and many plans may be underestimating its impact on Star Ratings.
Recent Star Ratings data from Plan Preview 2 (PP2) provides a cautionary tale. After the Colorectal Cancer Screening (COL) measure moved to ECDS-only reporting in 2024, its Star Rating cut points dropped across all thresholds by the maximum five points allowed under current guardrails—a clear sign that plan performance suffered when hybrid chart review was removed. As the National Committee for Quality Assurance (NCQA) continues to phase out hybrid measures through 2029, plans must rely solely on ECDS rather than end-of-year chart audits.
Here, as we await publication of the final 2026 Star Ratings, we explain why scores are dropping and offer strategies for MA plans to close out the calendar year with stronger performance.
MA Star Ratings have been on a downward trend recently, and the ECDS transition threatens to push them further down. The average overall MA-PD Star Rating dropped from 4.37 in 2022 to 4.07 in 2024, and down again to 3.92 in 2025. Only 40% of MA-PD plans earned 4 stars or higher for 2025, down from 68% just two years prior.
There are several factors driving Star averages downward. Most cut points have trended upward year-over-year since the COVID-19 pandemic provisions ended; low-performing plans have exited the market, raising cut points by removing the lower end of the distribution; and CMS has introduced changes to its calculation methodologies such as the Tukey outlier and cut point guardrails. On top of these factors, ECDS conversions add another barrier to improvement. When a high-performing measure drops in performance due to data issues, it drags down the plan’s overall rating.
Not being prepared for the ECDS transition is risky. Plans that fail to thoughtfully approach this transition will see rating drops not because care delivery actually suffered, but because they couldn’t prove the care happened in the new ECDS-only data era. In an environment where Star Ratings are increasingly hard to score well by design, plans can’t afford preventable errors in measure reporting.
With Q4 of 2025 upon us, there’s still time to mitigate the impact of the hybrid-to-ECDS change for this calendar year. The Eye Exam for Diabetic Patients (EED) measure is a prime example, since Measurement Year (MY) 2025 is the first year it must be reported with no hybrid supplementation. Plans should make a targeted, organizational push in Q4 to improve their EED rate before December 31. High -impact actions for EED and other measures include:
The transition from hybrid to ECDS reporting is a known shift that directly affects MA Star Ratings, with the fallout already being observed in 2026 Star Ratings preview data. While plans still have limited time in the calendar year to improve performance, adapting to the ECDS era will require long-term investments in integrated and predictive solutions that empower them to determine where to invest their limited resources to make the most impact. This will not only lead to higher quality scores in the future but directly drive improved member outcomes.
Don't miss the final entry in our 2025 Quality Decoded webinar series on Thursday, October 23 at 1 pm ET as we break down the latest Star Ratings results. Join us as we:
HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA).